Trial reportCardiovascular drugs and therapy2026
Opioid-Sparing Effects of Erector Spinae Plane Block in Off-Pump Coronary Artery Bypass Grafting with Median Sternotomy: A Randomized Controlled Trial.
Trial report in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study assessed the efficacy of preoperative erector spinae plane block (ESPB) in reducing intraoperative opioid use and enhancing recovery in off-pump coronary artery bypass grafting (OPCABG) patients, who typically require high-dose opioids with associated postoperative risks.
methodsA prospective, double-blind randomized controlled trial was conducted on 37 patients. Patients were randomized to receive either bilateral ESPB with 0.375% ropivacaine or a sham block with normal saline. Primary outcomes included intraoperative sufentanil consumption, while secondary outcomes encompassed hemodynamic stability, postoperative pain scores, mechanical ventilation (MV) duration, and hospital stay.
resultsThe ESPB group demonstrated a significant reduction in intraoperative sufentanil consumption compared to the sham group (150.3 ± 36.1 µg vs. 194.4 ± 38.3 µg, p = 0.001). Postoperatively, ESPB patients exhibited lower pain scores at rest and during coughing within the first 6 h post-extubation (p < 0.001) and required less rescue analgesia (5.3% vs. 50.0%, p = 0.003). Additionally, ESPB shortened MV duration (5.43 ± 1.65 h vs. 6.88 ± 1.68 h, p = 0.013). No significant differences were observed in cardiac care unit or hospital stay lengths.
conclusionPreoperative ESPB effectively reduces intraoperative opioid requirements and provides sustained analgesia in the early postoperative period, facilitating earlier extubation. These findings support ESPB as a valuable component of multimodal analgesia in OPCABG, though further large-scale studies are needed to validate these results and optimize its application. CLINICAL
trial registrationThe trial was registered with the China Clinical Trials Center ( http://www.chictr.org.cn , ChiCTR2200066902) on December 21, 2022.
Indexed as
Identifiers
40227473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.